查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080169

肢端肥大症：新型態療法、未滿足的需求與TPP洞察報告，2026年

Acromegaly - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 預計到 2035 年，法國肢端肥大症市場規模將從約 4.2 億美元成長到 6.3 億美元。
  • 以下因素正在推動市場成長：
  • 擴大生長抑制素類似物和標靶治療的應用
  • 改善慢性病的長期管理
  • 市場規模的擴大是由於治療持續時間延長和高品質生物製藥的出現。
  • 未來的成長取決於下一代內分泌療法和個人化治療策略。

肢端肥大症的新興療法及對TPP的深入研究

Thelansis 發布的「肢端肥大症：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026」對該適應症的關鍵新興療法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

肢端肥大症概述

肢端肥大症是一種進行性內分泌疾病，其特徵是進行性過度生長，通常由良性腦下垂體腺瘤引起的生長激素 (GH) 慢性過度分泌，導致胰島素樣生長因子 1 (IGF-1) 水平升高。由於起病緩慢，確診前通常需要 4 至 10 年的時間。如不治療，患者會出現肢體嚴重肥大、呈鏟形、臉部骨骼畸形、肥厚型心肌病和次發性糖尿病等全身性併發症。經蝶竇入路切除術仍是目前治療肢端肥大症的第一線標準方法。如果病灶持續存在或無法進行手術，則需要標靶藥物治療以使血液中 IGF-1 水平恢復正常。值得注意的是，長期以來需要每月注射的生長抑制素受體配體 (SRL) 藥物的壟斷地位已被打破。目前主流的治療方法是帕妥索汀，它是首個獲得FDA批准的每日一次口服非胜肽類SST2促效劑。長期數據顯示，口服帕妥索汀能夠強效且持久地控制生化指標並減輕常見的全身症狀，避免了傳統注射所帶來的併發症。對於病情嚴重或難治性病例，帕妥索汀可與口服卡麥角林合併使用，或升級至生長激素受體拮抗劑培維索孟，以防止全身結構劣化。

主要亮點

  • 根據預測，德國肢端肥大症的盛行率將從 2025 年的約 6,726 例增加到 2035 年的 7,022 例。
  • 肢端肥大症是一種罕見的內分泌疾病，主要由分泌生長激素的腦下垂體腺瘤所引起。
  • 由於症狀緩慢，診斷延誤仍然是一個重大挑戰。
  • 長期併發症包括心血管疾病、代謝失調和生活品質下降。
  • 醫療手段和疾病監測技術的進步提高了疾病控制率。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興療法條件的患者
  • 大公司
  • 主要作用機制
  • 發布日期等的預測
  • 臨床試驗現況分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要療法的有效性
  • 未滿足需求的關鍵領域
  • 主要未滿足需求的市場規模估算
  • 目標產品概況
  • 特徵和水平
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵意見領袖對領先新興療法的見解
  • 意識
  • 預期用途/處理線
  • 學位旨在解決重大未滿足的需求
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Alexion Pharmaceuticals, Inc.
  • Crinetics Pharmaceuticals Inc.
  • Camurus AB
  • Debiopharm International SA
  • Marea Therapeutics
  • Immunwork, Inc.

目錄

第1章：主要調查結果和分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要療法概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：初步調查

  • 目前治療狀態
  • 主要治療方法和目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興療法
  • 主要治療方法和目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興療法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Acromegaly Emerging Therapy and TPP Insights

Thelansis's "Acromegaly Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Acromegaly Overview

Acromegaly is an insidious endocrine disorder characterized by progressive somatic overgrowth driven by chronic growth hormone (GH) hypersecretion-typically from a benign pituitary adenoma-and subsequent elevation of insulin-like growth factor 1 (IGF-1). Because its onset is subtle, definitive diagnosis is notoriously delayed by four to ten years. Left unmanaged, patients develop distinctly enlarged, spade-like extremities, facial bone distortions, and systemic morbidities including hypertrophic cardiomyopathy and secondary diabetes mellitus. Transsphenoidal surgical resection remains the definitive first-line standard to remove the tumor. For persistent or inoperable disease, targeted medical management is required to normalize circulating IGF-1 levels. Crucially, the long-standing monopoly of painful, monthly injected somatostatin receptor ligands (SRLs) has been broken. The medical paradigm now centers on Palsonify (paltusotine), the first FDA-approved once-daily oral nonpeptide SST2 agonist. Backed by long-term data demonstrating robust, sustained biochemical control and reduced standard systemic symptoms, oral paltusotine bypasses conventional injection-site complications. For severe, non-responsive phenotypes, it can be combined with oral cabergoline or escalated to the GH receptor antagonist pegvisomant to prevent systemic structural degradation.

Key Highlights

  • In Germany, prevalent acromegaly cases are projected to increase from approximately 6,726 in 2025 to 7,022 by 2035.
  • Acromegaly is a rare endocrine disorder caused primarily by growth hormone-secreting pituitary adenomas.
  • Delayed diagnosis remains a major challenge due to the gradual onset of symptoms.
  • Long-term complications include cardiovascular disease, metabolic disorders, and reduced quality of life.
  • Advances in medical therapies and disease monitoring are improving disease control rates.

Market Overview

  • The France acromegaly market is projected to grow from approximately $420 MN to $630 MN by 2035.
  • Market growth is supported by:
  • Increasing utilization of somatostatin analogs and targeted therapies
  • Improved long-term management of chronic disease
  • Market value growth is driven by prolonged treatment duration and premium biologic therapies.
  • Future growth will depend on next-generation endocrine therapies and personalized treatment strategies.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Alexion Pharmaceuticals, Inc.
  • Crinetics Pharmaceuticals Inc.
  • Camurus AB
  • Debiopharm International SA
  • Marea Therapeutics
  • Immunwork, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)